Latest News and Press Releases

– Treatment with PYRUKYND® Associated with Early and Robust Hemoglobin Responses in Phase 3 ACTIVATE and Extension Studies; Approximately One-Third of Patients Achieved Normal Hemoglobin Levels at...

– Sarah Gheuens, M.D., Ph.D., to be Named Head of R&D, Chief Medical Officer; Chief Scientific Officer Bruce Car to Step Down at the End of July – – Company to Focus Internal Research Efforts on...

– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of PYRUKYND® (mitapivat) in Adults with PK Deficiency Who Do Not Receive Regular Transfusions – – Agios to...

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...

– Received U.S. FDA Approval for PYRUKYND®, the First Therapy for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) deficiency and Agios’ First Genetically Defined Disease...

CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...

– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND® Significantly Increased Hemoglobin Level, Decreased Hemolysis and Improved Patient-Reported Outcomes – –...

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases,...

– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder – – First...

– Approval Based on Results from ACTIVATE and ACTIVATE-T Phase 3 Studies, Supports Treatment of Adults with PK Deficiency Regardless of Transfusion Status – – Company to Provide Robust Patient Access...